Print this page
radiation
-
Impact of Early Radiation Oncology Involvement as Part of a Multidisciplinary Palliative Care Team on Quality of Life Among Diverse Patients with Advanced/Metastatic Malignancies.
Protocol: 002168Principal Investigator:
-
Malcolm Mattes
Applicable Disease Sites: Any Site -
A Phase II/III Randomized Study of R-miniCHOP With or Without Oral Azacitidine (CC-486) in Participants Age 75 years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIb Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements.
Protocol: 012103Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Study Protocol Cancer in Pregnancy (CIP-study)
Protocol: 012201Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
Fitness-Adapted, Pembrolizumab-Based Therapy for Untreated Classical Hodgkin Lymphoma Patients 60 Years of Age and Above.
Protocol: 012203Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma -
A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma.
Protocol: 012207Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Any Site -
Phase II study to assess the efficacy of combined tafasitamab and rituximab in front-line treatment of post-transplant lymphoproliferative disorder
Protocol: 012306Principal Investigator:
-
Joanna Rhodes
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
Phase 1/2 Study of Linvoseltamab (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple Myeloma (Linker-MM4 Study)
Protocol: 012310Principal Investigator:
-
Mansi R Shah
Applicable Disease Sites: Multiple Myeloma -
A Phase 3 Randomized Clinical Study of MK-4280A Coformulated Favezelimab MK-4280 plus Pembrolizumab MK-3475 Versus Physician's Choice Chemotherapy in PD-(L)1-Refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008).
Protocol: 012315Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Hodgkin's Lymphoma -
Social Genomic Mechanisms of Health Disparities among Adolescent and Young Adult (AYA) Survivors of Hodgkin and Non-Hodgkin Lymphoma.
Protocol: 012404Principal Investigator:
-
Andrew Evens
Applicable Disease Sites: Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma -
A Randomized, Open-Label Study Evaluating the Efficacy and Safety of Cemacabtagene Ansegedleucel in Participants with Minimal Residual Disease After Response to First Line Therapy for Large B-cell lymphoma.
Protocol: 012405Principal Investigator:
-
Matthew Matasar
Applicable Disease Sites: Non-Hodgkin's Lymphoma -
A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT-200 in Patients with Relapsed/refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High/Very High Risk Myelodysplastic Syndrome (MDS).
Protocol: 022204Principal Investigator:
-
Dale Schaar
Applicable Disease Sites: Myeloid and Monocytic Leukemia
Other Hematopoietic -
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-Like Tyrosine Kinase Mutation (FLT3 mut+): The FRIDA Study.
Protocol: 022301Principal Investigator:
-
Neil Palmisiano
Applicable Disease Sites: Myeloid and Monocytic Leukemia -
MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK).
Protocol: 032002Principal Investigator:
-
Matthew Deek
Applicable Disease Sites: Lung -
The Role of Adaptive Radiation Planning in Patients with Non-Small Cell Lung Cancer on Radiation Induced Toxicity .
Protocol: 032009Principal Investigator:
-
Salma Jabbour
Applicable Disease Sites: Lung -
A Phase I Study to Evaluate the Safety of Colchicine for Treatment and Prevention of Radiation-Induced Dermatitis.
Protocol: 032112Principal Investigator:
-
Bruce Haffty
Applicable Disease Sites: Lip, Oral Cavity and Pharynx -
Alternating Treatment Plans for Patients with Advanced Thoracic/HN Cancers (ATATcH).
Protocol: 032201Principal Investigator:
-
Missak Haigentz
Applicable Disease Sites: Lung